The subsidiary at this stage is likely only for ongoing innovation. Implementation is more than likely mostly the approval process for inclusion in its actual facility, and that work is likely all done and pending final confirmation, most likely either pending submission or pending approval, or collection of final data. And then implementation which is likely about payments and advent incorporating it into the plants development stages.
I doubt the number of employees remaining at Flaskworks is a determining factor with regard to pricing or a buyout. They already have the patents and are likely well along in terms of validation and probably it is already worked out as to what and when implementation for Sawston will occur. Any acquisition would certainly include that value, up to whatever stage of validation and implementation they are at including the acquisition value and IP value as it pertains to this company owning such IP. This includes also the fact that this technology certainly further extends NWBO’s likely control over the commercial implementation of DCVax in all of its forms for many more years since those patents are virtually all process patents and the Flaskworks patents extend and improve on all of those patents.
I own NWBO. My posts on iHub are always posted expressly as just my humble opinion (IMHO) and none are advice, just my opinion. I am NOT a financial advisor, and it is assumed that everyone is responsible for their own due diligence.
AI
